LIQUIDIA TECHNOLOGIES INC
NASDAQ: LQDA (Liquidia Corporation)
Last update: 2 hours ago29.11
0.55 (1.93%)
| Previous Close | 28.56 |
| Open | 28.06 |
| Volume | 2,173,611 |
| Avg. Volume (3M) | 2,579,732 |
| Market Cap | 2,532,438,528 |
| Price / Earnings (Forward) | 86.21 |
| Price / Sales | 36.61 |
| Price / Book | 117.01 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2025 | 8,565,638 |
| Caligan Partners Lp | 30 Sep 2025 | 8,118,892 |
| Findell Capital Management Llc | 30 Sep 2025 | 2,830,000 |
| Opaleye Management Inc. | 30 Sep 2025 | 2,615,000 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 1,710,084 |
| Caprock Group, Llc | 30 Sep 2025 | 1,632,089 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Needham, 78.63%) | Buy |
| Median | 50.00 (71.76%) | |
| Low | 49.00 (BTIG, 68.33%) | Buy |
| Average | 50.33 (72.90%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 27.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 04 Nov 2025 | 49.00 (68.33%) | Buy | 27.91 |
| HC Wainwright & Co. | 04 Nov 2025 | 50.00 (71.76%) | Buy | 27.91 |
| 06 Oct 2025 | 35.00 (20.23%) | Buy | 22.86 | |
| Needham | 04 Nov 2025 | 52.00 (78.63%) | Buy | 27.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Nov 2025 | Announcement | Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences |
| 03 Nov 2025 | Announcement | Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 27 Oct 2025 | Announcement | Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 |
| 07 Oct 2025 | Announcement | Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 |
| 29 Sep 2025 | Announcement | Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting |
| 11 Sep 2025 | Announcement | Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium |
| 27 Aug 2025 | Announcement | Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |